The CSM has advised of data associating the high-strength pancreatin preparations with the development of large bowel strictures in children with cystic fibrosis aged between 2 and 13 years and recommended that the total dose of pancreatic enzyme supplements used in patients with cystic fibrosis should not usually exceed 10,000 units of lipase per kg body-weight daily.
It is important to ensure adequate hydration at all times in patients receiving higher strength pancreatin preparations.
Additional NICE Guidance
NG49 (Jul 2016): Non-alcoholic fatty liver disease (NAFLD): assessment and management
NG50 (Jul 2016): Cirrhosis in over 16s: assessment and management
CG141 (Aug 2016): Acute upper gastrointestinal bleeding in over 16s: management